Today, Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for #Seizure Cessation Meets #PrimaryEndpoint
--- #Staccatoalprazolam achieved a statistically significant response rate. Avgerage time to seizure cessation was 30 secs https://t.co/NdkcqzbzTI
"#Staccatoalprazolam has demonstrated the ability to rapidly terminate seizures in patients with epilepsy in two minutes or less and prevent recurrence of seizure within two hours.” Read more by visiting our #news section on https://t.co/DT5BMWrbPJ to read the latest!
"The intent is to go to the FDA with an indication for people who need rapid control of seizure activity."
A Q&A with Jacqueline French of @nyulangone discusses recent findings of alprazolam 🧠:
https://t.co/0ySm8Vnm2K
Check out this important interview with our Principal Investigator, Dr. Jacqueline French, MD discussing the recent study findings from our Phase 2b trial of Staccato Alprazolam. #epilepsy#clinicalresearch#clinicaltrials
https://t.co/PLW9rW50EC
The president and CEO of @EngageEpilepsy, along with the company’s executive VP and COO, discussed its investigational Staccato alprazolam product in the abortive treatment of #seizures.
https://t.co/HAhDhfmLPt
For #PurpleDay for Epilepsy Awareness, we ask friends to donate $26 for the #1in26 Americans facing #epilepsy. We know many people & businesses are hurting, & we empathize. A RT also helps. We are #grateful, we are resilient & we are here! https://t.co/srAAx6ytlV
#virtualsupport
Another #innovator in #medtech charging ahead and making a difference in patients' lives and #healthcare. Congrats @EngageEpilepsy on your progress, we look forward to seeing you grow.
More on this innovator: https://t.co/lHvIRkDIZl
We are honored to be selected as an #innovation Leader at LSI’s Emerging #Medtech Summit 2020. Check out this article on our easy-to-use, hand-held drug-device combination product for use in the cessation of active and acute #epileptic#seizures.
https://t.co/7dc1imt8VX
ICYMI: @EngageEpilepsy has announced that its investigational abortive #seizure treatment Staccato #alprazolam has met its primary end point in the phase 2 StATES study.
https://t.co/VKX2yXAWzP
.@EngageEpilepsy has announced that its investigational abortive #seizure treatment Staccato #alprazolam has met its primary end point in the phase 2 StATES study.
https://t.co/VKX2yXAWzP
“We are now one step closer to bringing to patients an EpiPen® like rescue treatment that works fast enough to terminate an active seizure episode.” https://t.co/ZDzWfaUk01
For those with epilepsy: Im thrilled. An orally inhalable med by @EngageEpilepsy that can stop a seizure has finished stage 2 clinical trials. Results: Success in stopping for a statistically significant number of test subjects. On to outpatient tests. https://t.co/9DPmXFlGFh
It’s a particularly poignant win for Engage, which was founded by the father of a child with uncontrolled epilepsy in hopes that the company’s treatments will help tame his and other children’s seizures. https://t.co/hPvhDr1J7L